Colman R W, Figures W R, Scearce L M, Strimpler A M, Zhou F X, Rao A K
Blood. 1986 Aug;68(2):565-70.
The relative roles of platelet autacoids such as adenosine diphosphate (ADP), prostaglandin endoperoxides, and thromboxane A2 (TXA2) in collagen-induced platelet activation are not fully understood. We reexamined this relationship using the ADP affinity analogue, 5'-p-fluorosulfonylbenzoyl adenosine (FSBA), which covalently modifies a receptor for ADP on the platelet surface, thereby inhibiting ADP-induced platelet activation. Collagen-induced shape change, aggregation, and fibrinogen binding were each fully inhibited under conditions in which FSBA is covalently incorporated and could not be overcome by raising the collagen used to supramaximal concentrations. In contrast, TXA2 synthesis stimulated by collagen under conditions that produced maximum aggregation was only minimally inhibited by FSBA. Since covalent incorporation of FSBA has been previously shown to specifically inhibit ADP-induced activation of platelets, the present study supports the contention that ADP is required for collagen-induced platelet activation. Under similar conditions, indomethacin, an inhibitor of cyclooxygenase, inhibited collagen-induced shape change, indicating that endoperoxides and/or TXA2 also play a role in this response. Shape change induced by low concentrations (10 nmol/L) of the stable prostaglandin endoperoxide, azo-PGH2, was also inhibited by FSBA. These observations indicate a role for ADP in responses elicited by low concentrations of endoperoxides. However, at higher concentrations of azo-PGH2 (100 nmol/L), inhibition by FSBA could be overcome. Thus, the effect of collagen apparently has an absolute requirement for ADP for aggregation and fibrinogen binding and for both ADP and prostaglandins for shape change. Aggregation and fibrinogen binding induced by prostaglandin endoperoxides also required ADP as a mediator, but ADP is not absolutely required at high endoperoxide concentration to induce shape change.
血小板自分泌物质如二磷酸腺苷(ADP)、前列腺素内过氧化物和血栓素A2(TXA2)在胶原诱导的血小板激活中的相对作用尚未完全明确。我们使用ADP亲和类似物5'-对氟磺酰苯甲酰腺苷(FSBA)重新研究了这种关系,该物质可共价修饰血小板表面的ADP受体,从而抑制ADP诱导的血小板激活。在FSBA共价掺入的条件下,胶原诱导的形态变化、聚集和纤维蛋白原结合均被完全抑制,且提高胶原浓度至超最大浓度也无法克服这种抑制作用。相比之下,在产生最大聚集的条件下,胶原刺激的TXA2合成仅受到FSBA的轻微抑制。由于先前已证明FSBA的共价掺入可特异性抑制ADP诱导的血小板激活,本研究支持了这样的观点,即胶原诱导的血小板激活需要ADP。在类似条件下,环氧化酶抑制剂吲哚美辛抑制了胶原诱导的形态变化,表明内过氧化物和/或TXA2在该反应中也起作用。低浓度(10 nmol/L)的稳定前列腺素内过氧化物偶氮-PGH2诱导的形态变化也受到FSBA的抑制。这些观察结果表明ADP在低浓度内过氧化物引发的反应中起作用。然而,在较高浓度的偶氮-PGH2(100 nmol/L)下,FSBA的抑制作用可被克服。因此,胶原的作用显然对聚集和纤维蛋白原结合绝对需要ADP,而对形态变化则需要ADP和前列腺素两者。前列腺素内过氧化物诱导的聚集和纤维蛋白原结合也需要ADP作为介质,但在高浓度内过氧化物时,诱导形态变化并非绝对需要ADP。